Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation

International Journal of Experimental Pathology

Volumn 95, Issue 1, 2014, Pages 8-15

  Luo, Feijun ^a   Poulogiannis, George ^a,b   Ye, Hongtao ^a,c   Hamoudi, Rifat ^a   Dong, Gehong ^a   Zhang, Wenyan ^a   Ibrahim, Ashraf E K ^a   Arends, Mark J ^a,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

1, 2 dimethylhydrazine; Adenoma; Carcinogen; Colorectal; K ras; Mouse; Wild type

Indexed keywords

1,2 DIMETHYLHYDRAZINE; B RAF KINASE; CARCINOGEN; CASPASE 3; K RAS PROTEIN; KI 67 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CANCER SURVIVAL; COLORECTAL ADENOMA; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE DOSAGE; GENE INACTIVATION; GENETIC TRANSCRIPTION; HEMIZYGOSITY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MURINAE; NONHUMAN; ONCOGENE C MYC; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

1, 2-DIMETHYLHYDRAZINE; ADENOMA; CARCINOGEN; COLORECTAL; K-RAS; MOUSE; WILD-TYPE;

1,2-DIMETHYLHYDRAZINE; ADENOMA; ALLELES; ANIMALS; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE DOSAGE; HEMIZYGOTE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR SUPPRESSOR PROTEINS;

EID: 84893020858     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/iep.12064     Document Type: Article

References (35)

1. Arends M.J., McGregor A.H., Toft N.J. et al. (1993) Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br. J. Cancer 68, 1127-1133.
2. Arends M.J., McGregor A.H. & Wyllie A.H. (1994) Apoptosis is inversely related to necrosis and determines net growth in tumours bearing constitutively expressed myc, ras, and HPV oncogenes. Am. J. Pathol. 144, 1045-1057.
3. Baccichet A. & Sinnett D. (1997) Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia. Br. J. Haematol. 99, 107-114.
4. Campbell S.L., Khosravi-Far R., Rossman K.L. et al. (1998) Increasing complexity of Ras signaling. Oncogene 17, 1395-1413.
5. Classon M., Salama S., Gorka C. et al. (2000) Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc. Natl Acad. Sci. USA 97, 10820-10825.
6. Deschner E.E. & Long F.C. (1977) Colonic neoplasms in mice produced with six injections of 1, 2-dimethylhydrazine. Oncology 34, 255-257.
7. Deschner E.E., Long F.C. & Maskens A.P. (1979) Relationship between dose, time and tumor yield in mouse dimethylhydrazine-induced colon tumorigenesis. Cancer Lett. 8, 23-28.
8. Diaz R., Lue J., Mathews J. et al. (2005) Inhibition of Ras oncogenic activity by Ras protooncogenes. Int. J. Cancer 113, 241-248.
9. Diwan B.A., Meier H. & Blackman K.E. (1977) Genetic differences in the induction of colorectal tumors by 1, 2-dimethylhydrazine in inbred mice. J. Natl Cancer Inst. 59, 455-458.
10. Guerrero I., Villasante A., Corces V. et al. (1985) Loss of the normal N-ras allele in a mouse thymic lymphoma induced by a chemical carcinogen. Proc. Natl Acad. Sci. USA 82, 7810-7814.
11. Hurford R.K., Cobrinik D., Lee M.H. et al. (1997) pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev. 11, 1447-1463.
12. 6-alkylguanine DNA-alkyltransferase activity in normal colorectal tissue is associated with colorectal tumours containing a GCAT transition in the K-ras oncogene. Carcinogenesis 18, 1299-1302.
13. Jacoby R.F., Llor X., Teng B.-B. et al. (1991) Mutations in the K-ras oncogene induced by 1, 2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. J. Clin. Invest. 87, 624-630.
14. James R.M., Arends M.J., Plowman S. et al. (2003) K-ras proto-oncogene exhibits tumour suppressor activity as its absence promotes tumourigenesis in murine teratomas. Mol. Cancer Res. 1, 820-825.
15. Johnson L., Greenbaum D., Cichowski K. et al. (1997) K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11, 2468-2481.
16. Kibel A.S., Schutte M., Kern S.E. et al. (1998) Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res. 58, 5652-5655.
17. Luo F., Brooks D.G., Ye H. et al. (2007a) Conditional expression of mutated K-ras accelerates intestinal tumourigenesis in Msh2-deficient mice. Oncogene 26, 4415-4427.
18. Luo F., Hamoudi R., Brooks D.G. et al. (2007b) Stem cell gene expression changes induced specifically by mutated K-ras. Gene Expr. 14, 101-115.
19. Min mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int. J. Exp. Pathol. 90, 558-574.
20. Luo F., Ye H., Hamoudi R. et al. (2010) K-ras exon4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation. J. Pathol. 220, 542-550.
21. Luo F., Ye H., Hamoudi R. et al. (2011) Mutant K-ras promotes carcinogen-induced murine colorectal tumourigenesis, but does not alter tumour chromosome stability. J. Pathol. 223, 390-399.
22. Mahlamaki E.H., Hoglund M., Gorunova L. et al. (1997) Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosom. Cancer 20, 383-391.
23. Malumbres M. & Barbacid M. (2003) RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459-465.
24. Markman B., Javier R.F., Capdevila J. et al. (2010) EGFR and KRAS in colorectal cancer. Adv. Clin. Chem. 51, 71-119.
25. Marshall C. (1991) How does p21ras transform cells? Trends Genet. 7, 91-95.
26. Mason D.X., Jackson T.J. & Lin A.W. (2004) Molecular signature of oncogenic ras-induced senescence. Oncogene 23, 9238-9246.
27. Olson M.F. & Marais R. (2000) Ras protein signalling. Semin. Immunol. 12, 63-73.
28. Patek C.E., Arends M.J., Wallace W. et al. (2008) Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Exp. Cell Res. 314, 1105-1114.
29. Singh A., Sowjanya A.P. & Ramakrishna G. (2005) The wild-type Ras road ahead. FASEB J. 19, 161-169.
30. Sourvinos G., Kiaris H., Tsikkinis A. et al. (1997) Microsatellite instability and loss of heterozygosity in primary breast tumours. Tumour Biol. 18, 157-166.
31. Spandidos A. & Wilkie N.M. (1988) The normal human H-ras1 gene can act as an onco-suppressor. Br. J. Cancer Suppl. 9, 67-71.
32. Spandidos D.A., Frame M. & Wikie N.M. (1990) Expression of the normal H-ras1 gene can suppress the transformed and tumorigenic phenotypes induced by mutant ras genes. Anticancer Res. 10, 1543-1554.
33. Sun A., Bagella L., Tutton S. et al. (2007) From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J. Cell. Biochem. 102, 1400-1404.
34. Takeuchi S., Mori N., Koike M. et al. (1996) Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Res. 56, 738-740.
35. Zhang Z., Wang Y., Vikis H.G. et al. (2001) Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature 29, 25-33.